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The ability of cells to communicate and synchronise their activity is essential for the maintenance of 
tissue structure, integrity and function. A family of membrane-bound proteins called connexins are 
largely responsible for mediating the local transfer of information between cells. Assembled in the cell 
membrane as a hexameric connexon, they function either as a conduit for paracrine signalling, 
forming a trans-membrane hemi-channel or, if aligned with connexons on neighbouring cells, form a 
continuous aqueous pore, or gap junction, which allows for the direct transmission of metabolic and 
electrical signals. Regulation of connexin synthesis and activity is critical to cellular function and a 
number of diseases are attributed to changes in the expression and/or function of these important 
proteins. A link between hyperglycaemia, connexin expression, altered nucleotide concentrations and 
impaired function, highlights a potential role for connexin-mediated cell communication in 
complications of diabetes. In the diabetic kidney, glycaemic injury is the leading cause of end stage 
renal failure, reflecting multiple aetiologies including glomerular hyperfiltration, albuminuria, increased 
deposition of extracellular matrix, and tubulointerstitial fibrosis. Loss of connexin-mediated cell-to-cell 
communication in diabetic nephropathy may represent an early sign of disease progression, however, 
our understanding of the process remains severely limited. This review focusses on recent evidence 
demonstrating that glucose-evoked changes in connexin mediated cell communication and 
associated purinergic signalling, may contribute to the pathogenesis of kidney disease in diabetes, 
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Renal function depends on a high level of co-operativity between cells of the nephron. For cells to 
function efficiently and adapt appropriately in times of stress, they must not only interact with each 
other, but also with their immediate environment. Most cells communicate with their neighbours via 
gap junctions, or paracrine signalling [1-3]. Hemi-channels form as a result of hexameric clustering of 
membrane-bound proteins called connexins, which together form a trans-membrane pore more 
commonly termed a connexon [1]. When hemi-channels align with those on adjacent cells they ‘dock’ 
to form a gap junction. This junction facilitates the transmission of metabolic and electrical signals 
directly between cells, enabling cells to entrain their activity and synchronise tissue function. In the 
absence of neighbouring partners, uncoupled hemi-channels permit local paracrine release of 
nucleotides, including adenosine triphosphate (ATP) and its metabolites (adenosine diphosphate, 
ADP; adenosine monophosphate, AMP; and adenosine) (Figure 1) [2, 4]. 
 
Hemi-channel mediated release of nucleotides has multiple functions in the kidney, including 
regulation of renal blood flow, glomerular filtration rate and the regulation of renal tubular transport 
[reviewed in 3]. Derived from purinergic-mediated signals and activated in response to nucleotide 
binding to membrane-bound G-protein coupled purino-receptors (P1/adenosine and P2/ATP and 
ADP) on adjacent cells [4], increased hemi-channel activity and high levels of extracellular ATP have 
recently been linked to inflammation and fibrosis [5-7]. Aberrant connexin expression and the 
subsequent loss of cell function has been suggested to underpin the pathophysiology of multiple 
disease states, including diabetes, where glycaemic injury has been shown to decrease gap junction 
conductance and hemi-channel activity [8-10]. In light of this, connexins have received considerable 
attention in recent years, with suggestions that these proteins may represent a promising future 
therapeutic target for treatment of disease [11], including diabetic kidney disease; the leading cause 
of End Stage Renal Failure. 
 
Chronic kidney disease has been described as a global pandemic, with an estimated 850 million 
people worldwide thought to be affected by some form of kidney malfunction [12]. Diabetes is the 
biggest contributor to this statistic [12] with renal complications of the disease accounting for 
approximately 21% of deaths in patients with type1 diabetes, and approximately 11% in those with 
type2. Categorised into five stages and associated with a number of complex metabolic and 
inflammatory changes, diabetic nephropathy develops in response to defects at the molecular, cellular 
and tissue level in the vasculature, glomerulus and tubulointerstitium [13]. Whilst regulating blood 
sugar and blood pressure slow disease progression, many patients still develop renal failure even in 
the face of good glycaemic control. Consequently, as the incidence of diabetes continues to increase, 
there is a desperate need to improve therapeutic intervention to combat the long-term complications 
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of this lifelong metabolic disease. Changes in the expression profile of proteins involved in cell 
communication and associated downstream, purinergic signalling, may contribute to the development 
and progression of renal disease and thus represent a viable future target for intervention. In the 
current article, we review the expression, localisation and function of connexins, purinergic receptors 
and purinergic signalling in the diabetic kidney, and explore their underlying role as linked to the 
pathology of renal complications of diabetes. 
 
Connexins: The building blocks of cell-cell communication 
A family of trans-membrane proteins, connexins (CX) are designated by a numerical suffix that refers 
to their molecular weight. Expression may be ubiquitous, e.g. CX32 is expressed on various cell types 
including cardiac tissue, kidney and hepatocytes, or tissue specific, e.g. CX62 is only expressed in 
retinal tissue [14]. With a short half-life of only a few hours, connexins are continually synthesised and 
degraded, with biosynthesis and export to the cell membrane synonymous to that of other membrane-
bound proteins [15], ultimately allowing for acute regulation of channel activity and intercellular 
communication [15]. 
 
All connexins share common structural features and are composed of four trans-membrane helices, 
interconnected by two extracellular loops and one intracellular loop, a cytoplasmic -NH2 and a -COOH 
terminal region [16]. The highly conserved amino terminal tail incorporates a putative calmodulin-
binding motif necessary for both membrane insertion and, together with the -COOH terminal region, 
regulation of channel conductance, the latter of which is controlled by post-translational modification 
and phosphorylation of either serine/threonine or tyrosine residues [17-18]. When connexins combine, 
they oligomerise into hexameric channels. Comprised of six individual connexins, these trans-
membrane aqueous pores, 1-2nm in diameter, are permeable to a variety of small ions and molecules, 
including Ca2+, and IP3 and ATP [19]. 
 
Local release of ATP from hemi-channels was first identified by Gordan et al, who proposed that 
cellular efflux of the nucleoside triphosphate occurred in response to altered plasma membrane 
topography [20]. Further studies supported the notion that extrusion of ATP into the extracellular 
environment is a consequence of pore formation in the plasma membrane, pores later identified as 
“hemi-channels” [21]. Numerous connexins have since been implicated in the release of ATP, 
including CX26, CX32, and CX43 [reviewed in 22], and it is now widely accepted that hemi-channel 
release of purines, including ATP, adenosine and pyrimidine, can serve as paracrine signals for 
intercellular communication. These locally released purinergic signals bind one of three classes of 
receptor (metabotropic P1 receptors, P2Y metabotropic and P2X ionotropic receptors), activation of 
which initiates downstream signals linked to regulation of renal function [3]. More recently, a role for 
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extracellular nucleotides and paracrine signalling in organ fibrosis has been highlighted [5-7]. Not 
surprisingly, strict control of connexin activity is imperative in maintaining cellular function and is 
further supported by the observation that there are a large number of diseases where mutations 
and/or single nucleotide polymorphisms result in inflammation [23-24], ischaemia [25] and essential- 
[26] or renin-induced hypertension [27]. Consequently, hemi-channel gating is regulated in response 
to various stimuli including changes in cell proliferation, intracellular calcium, increased apoptosis, 
post-translational modification, changes in pH and in cell volume [reviewed in 1]. 
 
Connexin-mediated cell communication in the diabetic kidney 
With the incidence of diabetic nephropathy doubling over the last decade, it now accounts for 
approximately 50% of patients presenting with end stage renal failure [28-29]. Although the aetiology 
of type1 and type2 diabetes are notably distinct, glucose-evoked changes in the kidney are almost 
indistinguishable and often lead to a loss of renal function prompting the need for dialysis or 
transplantation. Diabetic nephropathy is characterised by structural and functional changes, 
specifically in the glomerulus, tubulointerstitium and vasculature, where glycaemic injury 
encompasses structural abnormalities ranging from hypertrophy, thickening of the glomerular 
basement membrane, tubular atrophy and interstitial fibrosis [30]. Ultimately, these changes 
contribute to increased glomerular filtration rate, proteinuria, systemic hypertension and overall, loss 
of renal function [30]. 
 
Our knowledge of connexin-mediated cell-to-cell communication in the kidney is limited. Whilst studies 
on renal vasculature have attributed a role for connexins in the regulation of blood pressure [31-34], 
we lack a basic understanding of the effects of connexin-mediated cell communication and associated 
purinergic signalling in tubular epithelia. Whilst a link between connexins and renal damage has 
recently emerged, how connexins contribute to the underlying pathology of chronic kidney disease 
remains to be confirmed. Of the known 21 mammalian connexin isoforms, only nine are expressed 
within the human kidney (CX26, CX30.3, CX31, CX32, CX37, CX40, CX43, CX45 and CX46 
[reviewed in 35]). A summary of their physiological functions in the kidney are listed in Table 1. 
 
Of the CX isoforms, high levels of expression of CX37, CX40 and CX43 are found in endothelial cells 
of the rat renal afferent arteriole, whilst post-glomerular endothelial cells of the efferent arteriole 
appear to express only CX43 [35]. The expression and localisation of particular subtypes can change. 
In the streptozotocin (STZ) treated mouse model of type1 diabetes, CX40 expression in smooth 
muscle cells of the afferent arteriole and inside the glomerulus increases, whilst endothelial 
expression of CX43 is decreased in the efferent arterioles [36-37]. These changes probably reflect 
the role of CX40 in regulating renin-dependent hypertension. Located in the juxtaglomerular 
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apparatus of the kidney, and part of the renin-angiotensin-aldosterone system involved in regulating 
blood pressure, renin-secreting cells are highly electrically coupled via CX40 mediated gap junctions 
[38-39]. Chronic changes in blood pressure necessitate recruitment of new renin-secreting cells from 
transformed smooth muscle cells associated with the pre-glomerular arterioles. This transformation 
is accompanied by increased expression of CX40 at the expense of CX45 [40]. Enhanced CX40 
expression is thought to increase cell-to-cell coupling between renin-secreting cells and their 
neighbours, including endothelial, smooth muscle and mesangial cells [40]. Loss of function defects 
in CX40 causes translocation of renin-secreting cells from the media layer of the afferent arteriole into 
the periglomerular interstitium. This translocation is thought to reduce negative feedback control by 
high blood pressure on renin secretion and further exacerbate hypertension. Although apparently 
counter-intuitive, these findings have been elegantly demonstrated in the CX40 knockout mouse 
model (CX40-/-), which develops hypertension [41]. Reasons for the shift of renin-secreting cells in the 
absence of CX40 and the subsequent loss of blood pressure regulation in response to enhanced 
renin secretion are unknown, however the work of Machura K et al. (2015), suggests that re-
localisation of cells probably arises as a consequence of disrupted connexin-mediated cell 
communication rather than enhanced activation of the renin angiotensinogen system [40]. Moreover, 
recent work by Haefliger JA et al. demonstrates that induction of renin-dependent hypertension, 
induced by clipping 1 renal artery in the 2-kidney, 1-clip (2K1C) model, is associated with increased 
aortic expression of CX43 [42]. A follow up study by the same group, was later to reveal that 
replacement of CX43 by CX32 is associated with decreased expression and secretion of renin, 
negating renin-dependent hypertension as previously observed in the wild-type 2K1C model [43]. 
Contrary to these findings, results from mice exhibiting deleted CX43 expression in both the 
endothelium and renin-secreting cells [44] fail to confirm a role for CX43 in either renin secretion or 
expression in mice maintained on a normal, or low salt diet ± an angiotensin I-converting enzyme 
inhibitor [44]. 
 
In addition to a role for CX40 and CX43, connexin 37 has also been shown to be localised to renin-
secreting cells and has also been linked to regulation of blood pressure. Studies using normotensive 
wild-type and CX37-deficient (CX37-/-) mice confirmed that the knockout mice were less hypertensive 
than their wild-type counterparts when infused with Angiotensin II (Ang II) over a 2-4-week period. 
Further clarification using the 2K1C renin-dependent model of hypertension, confirmed that CX37-/- 
mice rapidly recover a normal blood pressure, in spite of increased plasma renin levels. In contrast, 
in the renin-independent model of hypertension, mice remained hypertensive, suggesting that loss of 
CX37 most likely influences expression of proteins implicated in the Ang II pathway, notably the 
Angiotensin II receptor type II (AT2R) [45]. Moreover, studies using Ang II treated mesangial cells and 
an Ang II-induced mouse model of hypertension, confirmed renal damage as induced by activation of 
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several metabolic pathways, including increased CX43 expression which appeared dependent on 
activation of the RhoA/Rho-associated protein kinase (ROCK) pathway. Interestingly, incubation with 
an inhibitor of the RhoA/ROCK pathway; Fasudil, 2 weeks prior to the 4-week treatment time point 
returned CX43 expression levels to near basal and reduced the level of renal damage as observed 
to wild-type mice. However, mice remained hypertensive. Collectively, these data suggest a role for 
CX37 and CX43 in Ang II-induced renal damage [46]. 
 
Nitric oxide (NO) has been linked to the pathogenesis of disease in early diabetes [47-49]. Although 
intra-renal NO production is increased in the early phases of diabetic nephropathy, a progressive 
decline in NO production, specifically NO bioavailability in the kidney, is observed with advanced renal 
failure [50]. To decipher the interplay between connexins and endothelial nitric oxide synthase 
(eNOS), a nitric oxide synthase responsible for NO generation, a recent study by Le Gal L et al. 
utilised CX40-null mice combined with either the 1-Kidney, 1-clip (1K1C) procedure (a model of 
volume dependent hypertension), or the 2-kidney, 1-clip (2K1C) procedure (a model of renin-
dependent hypertension) [26]. In wild-type 1K1C mice, interactions between CX40, CX37 and eNOS 
were enhanced resulting in increased NO release. However, in mice lacking CX40, eNOS levels were 
decreased and an interaction between CX40 and eNOS was absent [26]. These data strongly suggest 
a role for CX40 mediated cell communication in regulation of NO synthesis, the effect of which 
manifests itself through loss of NO-induced vasodilation, and has been observed in other secondary 
complications of diabetes [51]. An additional role for NO in regulation of gap junction mediated 
intercellular communication (GJIC) in the mesangium has also been proposed. Yao et al. recently 
confirmed that increased NO augments CX43 mediated GJIC via protein kinase A [52]. Their 
observations are the first to suggest that diminished NO may, in part, mediate loss of CX43 mediated 
cell communication in the mesangium in diabetic nephropathy. The effects on overall mesangial cell 
function are yet to be clarified, however studies using the Zucker Lean and Zucker Diabetic Fat rat 
model of type2 diabetes, confirm both increased phosphorylation and inactivation of CX43 and 
reduced CX37 expression in renin-secreting cells, changes which were subsequently matched to 
increased glomerular filtration rate (GFR) and impaired auto-regulation [53]. 
 
Secondary to changes in the renal vasculature, an early hallmark of diabetic nephropathy is 
glomerulopathy, an important structural change characterised by thickening of the glomerular 
basement membrane, mesangial expansion, and development of morphological lesions in the 
arterioles, tubules and interstitium. Mesangial expansion is the structural parameter that best 
correlates with GFR and is also closely related to the presence of proteinuria and hypertension [54-
55]. Glomerular mesangial cells are highly coupled by CX43 containing gap junctions and various 
studies have examined a role for glucose in regulation of this protein and associated downstream 
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signalling molecules. The data provide a more detailed insight into how glucose-evoked alterations in 
renal connexins may, in part, contribute to loss of cell function. Furthermore, loss of CX43 expression 
has been linked to the G1 (senescence) phase of the cell cycle, a state of arrested cell growth linked 
to mesangial cell hypertrophy and accumulation of the extracellular matrix [56]. The effect was 
reversed when CX43 was over-expressed and the PTEN/Akt/mTOR pathway activated [57]. These 
data have been corroborated by Ya-Nan-Guo et al, who suggested that AMP-activated protein kinase 
(AMPK) mediated inhibition of mTOR, negates the loss of CX43 mediated signalling [58]. 
 
Knowledge of how connexins mediate their effects through interaction with associated downstream 
signalling molecules is improving, as is our understanding of how connexin expression/function 
becomes compromised in disease. Connexins are multifunctional proteins that contribute to a large 
number of cell functions including, proliferation, cell adhesion and cell migration. Phosphorylated on 
tyrosine residues Tyr265 and Tyr247 by the non-receptor tyrosine kinase c-Src, phosphorylation of 
CX43 inactivates the channel and reduces GJIC [59-60]. Elevated in patients with diabetes, c-Src has 
been linked to the pathogenesis of diabetic nephropathy [61]. Studies by Xie et al. confirm that 
inhibition of c-Src, not only attenuates the up-regulation of glucose-induced intercellular adhesion 
molecule-1 (ICAM-1), transforming growth factor-beta 1 (TGF-β1) and fibronectin expression in 
glomerular mesangial cells, but it also promotes Nuclear Factor-kappa B (NFκB) activation, leading 
to renal inflammation. These effects were negated when CX43 was over-expressed [62]. Whilst NFκB 
is increased in kidneys of STZ-diabetic rats and glucose treated glomerular mesangial cells, the 
mechanisms by which this transcription factor mediates its effects remain elusive. The small GTPase 
RhoA, is a member of the Ras superfamily [63]. Rho-associated protein kinase (ROCK) is a 
serine/threonine kinase and downstream target of RhoA. Signalling via RhoA/ROCK regulates 
multiple cell functions, including cell migration, contraction, adhesion, gene expression and cell cycle 
progression. Furthermore, RhoA/ROCK signalling has been linked to the pathogenesis of diabetic 
nephropathy, with ROCK inhibitors Y27632 and Fasudil negating the accumulation extracellular 
matrix and preventing a loss of renal function [64]. In addition to its role in controlling deposition of 
fibrotic material and up-regulation of pro-fibrotic factors in the kidney, recent studies by Xie et al. 
identified that low levels of CX43 induce NFκB activation in response to high glucose [65]. They 
reported that up-regulation of CX43 inhibited the nuclear translocation of the NFκB p65 subunit, an 
effect attenuated when RhoA/ROCK signalling was blocked. Furthermore, increased F-actin 
accumulation and an enhanced association between CX43 and tight junction protein zona occludens-
1 (ZO-1) in glucose treated cells was observed [65]. Xie et al. concluded that activated RhoA/ROCK 
signalling mediates CX43 degradation and nuclear translocation of NFκB p65, by promoting 
association between ZO-1 and CX43, which ultimately triggers CX43 endocytosis and NFκB activation 
in glucose treated cells, subsequently resulting in inflammation. These studies confirm that high 
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glucose impairs CX43 expression, with subsequent cell cycle arrest, inhibition of proliferation, 
promotion of protein synthesis, hypertrophy of the mesangium and NFκB mediated inflammation. 
Whilst these findings suggest that targeting CX43 may protect against mesangial cell hypertrophy and 
expansion in the diabetic kidney [65], it is important to remember that mesangial cells and their matrix 
constitute the main body of the glomerulus and work closely with both neighbouring podocytes and 
endothelial cells in ensuring appropriate glomerular function is maintained [66]. Consequently, 
alterations to either structural or behavioural characteristics will undoubtedly impinge on the behaviour 
of other cell types and may contribute to initial diagnosis of nephropathy as evidenced by detection 
of albuminuria [67]. 
 
Located within the glomerulus, podocytes have long cytoplasmic processes, which extend from the 
main cell body and divide into individual foot processes (pedicels). In healthy kidneys, the distance 
between these adjacent foot processes varies from 25nm to 60nm, a gap bridged by a thin membrane 
more commonly referred to as the “slit diaphragm”. Initiated in response to podocyte injury, breakdown 
of this selective filtration barrier results in albumin appearing in the urine [68]. Although we lack 
definitive information of how connexins are regulated within podocytes, evidence suggests that these 
trans-membrane proteins may represent viable markers for assessment of early podocyte damage in 
diabetic kidney disease. Connexin 43 is expressed on podocytes in both normal and diseased kidney 
[69-70], and a role for connexins in podocyte injury has been suggested. Studies by Yaoita E et al., 
demonstrated increased expression of CX43 in the early nephrotic stage of puromycine 
aminonucleoside (PAN) induced nephrosis [71], effects mediated, in part, by generation of superoxide 
and NADPH oxidase 4 (NOX4) [71]. Corroboration for the role for CX43 as a marker of podocyte 
damage has been further provided by Sawai et al., who demonstrated that expression of CX43 in 
renal biopsies and podocytes from patients with overt nephropathy, was reduced. This loss of 
expression would impair podocyte cell communication and contribute to the loss of barrier function 
and ultimately albuminuria [72]. Furthermore, they hypothesised that altered association between 
CX43, tight junctions and cytoskeletal proteins, are responsible for disrupting the orientation of slit 
diaphragm components, thus contributing to loss of the selective filtering process. The findings 
support the use of CX43 as a potential marker in assessing both podocyte damage and renal function 
in diabetic nephropathy. 
 
Whilst the structural and functional disturbances discussed above are synonymous with early stages 
of diabetic nephropathy, tubulointerstitial fibrosis represents the final common pathway of chronic 
renal failure and exhibits a positive correlation to the onset of end-stage renal disease and entry onto 
the renal transplantation programme [73]. Recent findings from our laboratory confirm that tubular 
CX43 and CX26 expression are increased in biopsy material from people with diabetic nephropathy 
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[74], and work by Abed A et al. reported that patients with chronic kidney disease (CKD) exhibit 
elevated levels of CX43. Using a mouse model of hypertension-induced CKD, they demonstrated 
decreased expression of cell adhesion markers, reduced monocyte infiltration and interstitial renal 
fibrosis when CX43 expression was reduced by 50%. Functional and histological parameters such as 
glomerulosclerosis and albuminuria were also reduced [75]. Although not a model of glycaemic injury, 
these data, along with our in vitro findings, suggest that aberrant CX43 mediated cell communication 
may have implications for the pathology of multiple forms of CKD via a common pathway. 
 
How aberrant CX mediated communication impacts on cell function forms the basis of our ongoing 
studies. In early tubulointerstitial fibrosis, exposure to glucose and downstream pro-fibrotic cytokines 
initiates a series of events beginning with altered expression of the epithelial adhesion protein E-
cadherin [74][76]. Cadherins help form the multi-protein adherens-junction that links cell-to-cell 
contact to the actin cytoskeleton and associated signalling molecules. It is therefore unsurprising that 
intercellular adhesion is a pre-requisite for connexin oligomerisation and gap junction formation. The 
loss of cell adhesion is the driving force behind morphological and phenotypic changes associated 
with early tubular injury [74], and has been linked to glucose-evoked changes in connexin expression 
and GJIC [74]. Although more than a dozen fibrogenic factors affect renal function, it is widely 
recognised that TGF-β1 and downstream Smad signalling, represent the key pathway orchestrating 
renal fibrosis in diabetic nephropathy [reviewed in 77-78]. Recent studies from our laboratory, confirm 
that TGF-β1 evoked changes in E-cadherin mediated cell adhesion facilitate changes in CX43 
expression in human proximal tubule cells via a Smad dependent signalling [5]. Whilst the functional 
loss in cell tethering was accompanied a loss of CX43 GJIC at both 48hrs and 7days, hemi-channel 
mediated ATP release was increased [5]. 
 
In addition to early changes that initiate injury in the proximal region, one of the hallmarks of 
tubulointerstitial fibrosis is the accumulation of the extracellular matrix (ECM) in the tubular 
interstitium. Under physiological conditions, increased ECM deposition is associated with wound 
healing [79] and thus a tight balance between synthesis and breakdown of matrix proteins ensures 
that once the wound is closed, further ECM production ceases. Loss of this regulation can tip the 
balance from repair to injury, culminating in a build-up of fibrotic material, scar formation and in the 
kidney, a decline in excretory function [80-82]. As a mechanical framework that provides physical 
support for cells, the ECM has a crucial role in regulating cellular behaviour, e.g. gene expression, 
cell adhesion and cell communication [83-84]. Predominantly composed of laminin, collagen, 
fibrinogen and fibronectin, ECM proteins can interact with cell surface receptors called integrins. 
Association not only provides an anchor between the cytoskeleton and the cells immediate 
environment, to enable traction and cell movement, but also directly regulates cell signalling. Whilst 
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connexin mediated cell communication is essential for cell survival and function, cell-ECM interactions 
facilitate the activation of growth factors and cell differentiation. Interestingly, modification and 
remodelling of the ECM in disease can severely impact on function, with recent studies identifying a 
link between high glucose, ECM remodelling and disrupted GJIC in multiple disease states, including 
secondary complications of diabetes [85][86]. Here, remodelling of the ECM occurs in response to 
prolonged alterations in the activity of matrix metalloproteinases (MMPs), zinc-dependent 
endopeptidases that control both synthesis and degradation of ECM components. Recent studies 
have confirmed that increased MMP9 induces ECM remodelling, an event linked to a down-regulation 
of hydrogen sulphide (H2S) [87]. Low H2S is associated with vascular inflammation and renal 
complications in diabetes [88]. It is correlated to decreased expression of CX40 and CX43 in the 
diabetic kidney which, along with ECM remodelling and dysregulated MMP expression, can be 
negated in the Akita mouse treated with NaHS, a soluble source of H2S provided in drinking water 
[89]. Administration of exogenous H2S improves renal function and reduces the degree of ECM 
remodelling [90][91]. Although the link between connexins and ECM remodelling in the diabetic kidney 
is just coming to light, our knowledge of the area in retinopathy, combined with increasing awareness 




ATP and purinergic signalling in the diabetic kidney. 
 
Adenosine triphosphate is a ubiquitous source of energy found in all cells. Usually present in low 
millimolar concentrations [92], decreases in intracellular ATP are synonymous with cell death and the 
dramatic release of ATP into the extracellular environment is often associated with cell injury triggered 
by stressors including, inflammation, hypoxia or mechanical deformation. In addition to its role as an 
energy supply and marker of cell damage, the controlled release of ATP and associated purines also 
act as autocrine/paracrine extracellular messengers capable of binding to purinoreceptors on 
adjacent cells to help propagate cellular activity. 
 
In the kidney, ATP is released from a variety of sources including, erythrocytes, endothelial cells, 
aggregating platelets and the basolateral and apical membrane of epithelial cells [93]. With a wealth 
of information attributing dysregulated connexin expression to the effects of hyperglycaemia, recent 
studies further highlight  a link between hemi-channel mediated ATP release and the progression and 
development of fibrosis in multiple tissue types, including the diabetic kidney [94-95] where hemi-
channel mediated ATP release may, in part, contribute to the pathology of diabetic nephropathy. 
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Purinergic signals bind to one of 3 receptor subclasses, the metabotropic P1 receptors, the P2Y 
metabotropic receptors or the P2X ionotropic receptors [96]. The P2 class of receptors can be further 
classified into either P2X (P2X 1-7) or P2Y (P2Y1, 2, 4, 6, 11-14). Activated in response to various agonists, 
P2Y receptors couple to either cAMP or inositol triphosphate (IP3) messenger systems, with each 
subtype functionally linked to different G-proteins evoking downstream activation of multiple signalling 
cascades. The precise location of specific receptor subtypes able to respond to these local signals is 
unclear. Some, including the P2X7 receptor, appear up-regulated in various diseases [97-102], 
including diabetic nephropathy, where renal P2X7R expression has been found to be associated with 
severe mesangial expansion, impaired glomerular filtration (≤40ml/min/1.73sq.m.) and increased 
interstitial fibrosis in diabetic patients [103]. Furthermore, activation of P2X7R increased MCP-1 
release in human mesangial cells when cultured under high glucose [103]. 
 
Expression of P2X7 in kidneys from streptozotocin (STZ) induced diabetic rats, is elevated in 
glomerular podocytes, mesangial cells and endothelial cells [104]. High levels of P2X7 mRNA in rat 
glomerulonephritis has been linked to increased IL-1b mRNA and exacerbated glomerular damage 
[105]. More recently, Vieira et al., suggested that P2X7 mediated inflammation and fibrosis in response 
to glycaemic injury in diabetic kidney disease [105]. In this elegant study, they demonstrated that P2X7 
deficient mice (-/-) are resistant to STZ-induced diabetes and fail to exhibit any alterations to blood 
glucose levels or pancreatic islet reduction compared to wild-type C57BL/6 mice. Not surprisingly, 
levels of pro-inflammatory mediators, including IL-1b, IFN-g and NO, were unaltered in P2X7-/- animals 
following STZ treatment. Using a P2X7 antagonist, wild-type C57BL/6 mice exhibited resistance to 
STZ treatment. Pharmacologically blocking the receptor, or deleting its expression, is linked to a 
reduction in renal macrophage activity and subsequently protects against antibody-mediated 
glomerular inflammation [106, 107]. These data have been supported by Menzies et al. in a mouse 
model of diabetic nephropathy, which when treated with a P2X7R inhibitor (AZ11657312) exhibit 
reduced renal macrophage accrual [108]. 
 
Efficient and effective purinergic signalling is dependent on a balance between ATP release and 
breakdown. Ectonucleotidases are a class of enzymes, which metabolise nucleotides to nucleosides 
[109]. The contribution of ectonucleotidases in the modulation of purinergic signalling depends on the 
availability and preference of substrates and on the cell and tissue distribution. Ectonucleoside 
triphosphate diphosphohydrolase 1 (ENTPD1), otherwise referred to as CD39, is a human 
membrane-bound protein, which hydrolyses ATP and ADP to AMP, thus regulating P2Y ligand 
availability [110]. Studies on the CD39 null mice reveal a large degree of renal damage in the form of 
glomerulosclerosis [111]. The mice present with increased proteinuria, increased GFR and increased 
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expression of monocyte chemo-attractant protein-1 (MCP-1), all of which were more severe than 
changes observed in aged matched diabetic animals. The data suggests a potential protective role 
for the hydrolysing enzyme in glomerular inflammation. Genetic deletions of the adenosine A2B 
receptor and CD73 (an enzyme involved in the extracellular production of adenosine) in mice, was 
found to induce renal nephropathy [78][110]. Studies examining a role for ATP in mesangial cell 
proliferation and expansion, contributory factors in the instigation of glomerulosclerosis, confirmed 
that ATP induced mesangial cell proliferation was mediated by P2Y receptor dependent activation of 
the Ras-Raf-MAPK signal transduction pathway [112] and P2Y4 [113]. Recently, a role for P2X7 in 
modulating the microvasculature response [114] and renal metabolism of extracellular adenine 
nucleotides in diabetic rats [114] has been examined. Findings confirmed, that in kidneys obtained 
from STZ-induced diabetic mice, increased levels of adenosine, ENTDPase and 5’-nucleotidase 
paralleled decreased levels of ATP in the renal interstitial fluid. More importantly, the effects were 
abolished by A438079, a P2X7 receptor antagonist [114]. 
 
In tubulointerstitial fibrosis , early tubular injury occurs in response to changes in adhesion, and cell-
substrate interactions [30]. Adhesiveness between cells and between cells and their surrounding 
substrate/ECM-matrix, allows them to adapt to their immediate environment [reviewed in 115]. Not 
surprisingly in diabetic nephropathy, loss of cell adhesion, increased synthesis of ECM proteins and 
ECM remodelling have all been linked to a loss of epithelial phenotypic stability and increased fibrosis 
in the proximal tubular region of the kidney [30]. Our recent studies identified that a switch in direct 
gap junction intercellular communication accompanies a loss of E-cadherin mediated cell adhesion 
and increased hemi-channel mediated ATP release. Linked to inflammation and fibrosis, incubation 
of proximal tubule epithelial cells with non-hydrolysable ATPgS confirmed an increase in expression 
of the pro-inflammatory and pro-fibrotic mediators interleukin-6 (IL-6) and fibronectin. Similarly, the 
ectonucleotidase apyrase, negated the IL-6 and fibronectin response to TGFb1 at both 48hrs and 
7days [5]. In addition, a direct role for ATP in ECM remodelling has been suggested by studies in rat 
mesangial cells demonstrating increased P2X4 induced activation of the NOD-like receptor 3 (NLRP3) 
inflammasome, increased release of interleukins IL-1β and IL-18 and the development of 
tubulointerstitial inflammation [116, 117]. High glucose increased expression of NLRP3 
inflammasome and interleukin IL-1b in human kidney (HK2) proximal tubular epithelial cells, with 
increased secretion of both interleukins IL-1b and IL-18. The effects were negated when cells were 
co-incubated with apyrase. Confirmation of the purinoreceptor that mediated these effects was 
provided when NLRP3 expression and IL-1β and IL-18 release was attenuated by co-incubating cells 
with the general P2X receptor antagonist TNP-ATP, or the more selective P2X4 antagonist 5-BDBD, 
or through gene silencing of P2X4 [118]. The data suggest that ATP-P2X4 signalling mediates high 
	 15 
glucose-induced activation of the NLRP3 inflammasome, regulates IL-1 family cytokine secretion, and 
ultimately instigates tubulointerstitial inflammation in diabetic nephropathy. These are important 
findings since patients with type2 diabetes and nephropathy reportedly exhibit elevated receptor 
expression of P2X4, P2X7 and NLPR3 expression [119]. Links to the P2X7 receptor have also been 
provided in studies using the P2X7 receptor knockout mouse model of unilateral ureteral obstruction 
(UUO), in which animals present with progressive renal fibrosis, marked renal hemodynamic and 
metabolic changes, tubular injury and cell death [118]. These mice exhibit reduced myofibroblast 
number, collagen deposition, tubular apoptosis and macrophage infiltration. Collectively the data 
suggest a role for the P2X7 receptor in progression of inflammation and fibrosis. In a similar study, 
Solini et al. confirmed that rat mesangial cells (RMCs) cultured in high (30mmol/L) glucose exhibit 
increased extracellular ATP [119]. Under both low and high glucose, exogenous application of ATP 
and the P2X7 receptor agonist benzoylbenzoyl ATP, evoked a concentration dependent increase in 
the ECM markers, fibronectin, collagen IV, laminin and TGFβ. The effects were negated when RMCs 
cultured in high glucose were co-incubated with apyrase. Interestingly, extracellular matrix and TGFβ 
production remained unaltered in response to apyrase treatment in cells cultured under low glucose. 
A role for P2X7 in mediating fibrotic changes was suggested by co-incubating with a P2X7 inhibitor, 
which attenuated glucose-induced increases in ECM and TGFb [119]. 
 
Aside to a potential role for hemi-channel mediated ATP release and dysregulated purinergic 
signalling in the early portion of the nephron, recent studies by Ponnusamy et al. suggest a role for 
nucleotides in P2R-mediated cross talk between epithelial cells and fibroblasts [120], whilst studies 
by Wolff et al. suggest a role for P2Y2 receptors in TGF-β1 induced EMT in Madin Darby Kidney Cells 
(MDCK) [121]. 
 
Lastly, whilst a definitive link between aberrant hemi-channel mediated ATP release and the 
underlying pathology of diabetic nephropathy remains to be confirmed, studies utilising models of 
glomerulosclerosis and advanced interstitial inflammation/fibrosis (UUO), pathologies associated with 
diabetic kidney disease, have used pharmacological and genetic strategies to assess the implications 
of aberrant Cx43 mediated communication. In a model of glomerular damage, Kavvadas et al. 
confirmed increased de novo expression of Cx43 in podocytes, which led to cell damage and 
deterioration of renal function, a response which was blunted in heterogenous mice in which Cx43 
expression had been genetically repressed (Cx43+/-). More importantly, pharmacogenetic inhibition of 
Cx43 delayed renal structural and functional damages in mice suffering from severe GN and in 
cultured podocytes treated with TGF-b1 [122]. In addition and in confirming a role for Cx43 in the 
progression of CKD, administration of a Cx43 antisense in a mouse model of UUO attenuated E-
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cadherin down-regulation and phosphorylation of the transcription factor Sp1 by the ERK pathway, 
resulting in decreased transcription of the type I collagen gene. Furthermore, Cx43-hemi-channel 
specific blocking peptide Gap19 inhibited monocyte adhesion in activated endothelium and pro-
fibrotic pathways in tubular cells, thus suggesting that modulation of both connexin-mediated cell 
communication and purinergic signalling may represent a novel approach to preventing or attenuating 




To ensure efficient renal function is maintained, cells of the nephron synchronise their activity and 
coordinate function within different regions of the nephron through the use of connexins. Cells 
communicate to one another either directly, via gap junction mediated intercellular communication, or 
via a hemi-channel mediated paracrine release of nucleotides in to the immediate extracellular 
environment. In diabetic nephropathy, these small membrane-bound proteins play a vital role in 
orchestrating an integrated functional response against fibrotic, osmotic and metabolic assault. In the 
current article, we review growing evidence to suggest that dysregulated connexin mediated cell 
communication and altered purinergic signalling may be pivotal in the aetiology and pathogenesis of 
diabetic nephropathy. Our understanding of the complex interplay between connexins, nucleotide 
release and downstream purinergic signalling in hyperglycaemia remains rudimentary, however, it is 
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Figure 1. Connexin-mediated intercellular communication. Hemi-channels form the hexameric 
arrangement (connexon) of membrane bound proteins called connexins. Hemi-channels permit the 
efflux of small molecules (e.g. ATP) in to the intercellular micro-environment immediately surrounding 
cells. These local paracrine signals can be detected by receptors on adjacent cells, e.g. P2Y 
receptors, which help propogate and synchronise activity across cell clusters. When aligned with 
similar channels on neighbouring cells, hemi-channels form continuous pores or gap junction that 





Cx Isoform Physiological Function 
26 Tubular localisation determined but function still to be determined 
30 Tubular release of ATP to regulate salt and water reabsorption in the 
distal nephron  
37 Vascular-conducted responses, in particular arteriolar vasoconstriction  
Endothelium-derived vasodilation, via production of eNOS or 
hyperpolarisation 
Renal autoregulation, via tubuloglomerular feedback 
Possible tubular function, regulation by salt  
40 Vascular-conducted responses, in particular arteriolar vasodilation 
Endothelium-derived vasodilation via inhibition of endothelium-derived 
hyperpolarising factor, production of eNOS 
Renal autoregulation via tubuloglomerular feedback and myogenic 
responses 
Blood pressure control via regulation of renin secretion 
43 Endothelium-derived vasodilation via inhibition of endothelium-derived 
hyperpolarising factor, possibly via production of eNOS 
Renal autoregulation through tubuloglomerular feedback and myogenic 
responses 
Blood pressure control, although mechanisms are still disputed 
Tubular function, dysregulation of which is associated with fibrosis and 
inflammation  
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